6-Fluoro-AMT
| Clinical data | |
|---|---|
| Other names | 6-Fluoro-AMT; 6-Fluoro-αMT; 6F-AMT; 6F-αMT; 6-F-AMT; 6-F-αMT |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H13FN2 |
| Molar mass | 192.237 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-Fluoro-α-methyltryptamine (6-fluoro-AMT, 6F-AMT) is a tryptamine derivative related to compounds such as α-methyltryptamine (AMT) and 5-MeO-AMT which has been sold as a designer drug.
Animal tests showed the drug to be somewhat less potent in terms of pharmacological activity than AMT or 5-fluoro-AMT. It produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents. Its IC50 for monoamine oxidase A (MAO-A) inhibition is 580 to 1,800 nM, compared to 180 to 450 nM for 5-fluoro-AMT and 380 nM for AMT.
6-Fluoro-AMT was allegedly manufactured and sold from the laboratory operated by Leonard Pickard and Gordon Todd Skinner, who described 6-fluoro-AMT as "a beast". In interviews, Skinner stated that he first began to experiment with 6-fluoro-AMT in the early 1980s by giving it to high school friends. Their experiences made him cautious about the appropriate doses, which he said ranged from 25 to 75 mg (Skinner weighed about 250 lbs at the time of his own bioassay). Skinner said that 6-fluoro-AMT is a long-lasting psychedelic with more time distortion and that it was enhanced by combination with ALD-52.
6-Fluoro-AMT was first described in the scientific literature, by Asher Kalir and Stephen Szara, by at least 1963.